A Randomized Phase 3 Study of LY2835219 Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

Trial Profile

A Randomized Phase 3 Study of LY2835219 Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms JUNIPER
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Oct 2017 According to an Eli Lilly media release, company will submit the data for presentation at a medical meeting in 2018.
    • 10 Oct 2017 Results presented in an Eli Lilly media release.
    • 10 Oct 2017 Primary endpoint (Overall Survival) has not been met , according to an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top